Drugs / TQB2916
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05213767 | Feb 2022 → May 2023 | — | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06962267 | Apr 2025 → Aug 2027 expected | malignant pancreatic neoplasm | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06500091 | Jul 2024 → Jun 2026 overdue | melanoma, soft tissue sarcoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024 AACR 前瞻 | 正大天晴创新药安罗替尼、TQB2916（CD40激动剂）共5项研究将亮相国际舞台 cttq.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2916 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06962267 ↗ |
| Action | Activate | “CD40 agonist” NCT05213767 ↗ |
| Modality | Monoclonal antibody | “humanized immunoglobulinG2 (IgG2) monoclonal antibody” NCT05213767 ↗ |
| Target | CD40 | “monoclonal antibody targeting CD40” NCT05213767 ↗ |